JAK2 and type 2 diabetes mellitus: Here, in the T2D patients receiving glucose-lowering drugs, both increased phosphorylation of the upstream molecule JAK-2 and of the downstream MAPK (p38 MAPK) were observed for the first time in this clinical context.